TSX News -
ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
TORONTO and CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company […]